Efficacy and safety of QGE031 versus placebo in patients aged 18-75 years with asthma not adequately controlled with standard of care medication (inhaled corticosteroids plus long lasting beta agonists with or without oral corticosteroids)

Registry ID

EUCTR2014-003155-57

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2015-10-09

Completion date

2016-03-07

Last update

2026-08-16

Conditions

• Severe Asthma

Summary

To evaluate effect on the reduction in rate of severe asthma exacerbations of different dose levels of QGE031 in asthma patients that are inadequately controlled with inhaled steroid plus beta-2 agonist medication with or without oral steroid. Safety will also be assessed. Comparison will be to placebo.

Locations

• , , UK
• , , Hungary
• , , Italy
• , , Germany
• , , Belgium
• , , Spain
• , , Slovakia
• , , Netherlands
• , , Luxembourg

Related clinical trials

• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
• Physical Activity Promotion and Clinical Remission in Severe Asthma
• A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
• Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes
• Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)

View on source registry